NCT05329285Recruiting
CABG or PCI in Patients With Ischemic Cardiomyopathy
CABG or PCI in Patients With Ischemic Cardiomyopathy - A Randomized Registry Clinical Trial
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
The STICH-SWEDEHEART trial will compare PCI vs CABG for revascularization of patients with HF and LV systolic dysfunction (LV ejection fraction (LVEF) \<40%) and multi-vessel coronary artery disease.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 470 (estimated)
- First submitted
- 17 Mar 2022
- Start date
- 14 Sept 2022
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Vastra Gotaland Region
- Diseases
- Coronary artery disease
- NCT number
- NCT05329285
What you commit to
- Study type: Interventional
- Planned participants: 470
- From 14 Sept 2022 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous randomization in the study
- Decompensated heart failure requiring inotropic /adrenergic support, invasive or non-invasive ventilation or intra-aortic balloon pump/ventricular assist device therapy less than 48 hours prior to randomization
Other illness
- Recent (\<1 month) type 1 myocardial infarction
- Valvular heart disease or any other cardiac conditions (e.g. LV aneurysm) requiring surgical repair/replacement
- Prohibitive bleeding risk or clinical scenario mandating avoidance of long-term dual antiplatelet therapy
- Expected survival less than 3 years due to non-cardiac illness
Other
- Recent PCI (\<3 months)
- Circumstances likely to lead to poor treatment compliance
- Individuals for whom record in public health databases is not accessible (non-eligibility to public health system, parallel healthcare systems
- Pregnancy or woman of childbearing potential who is not sterilized or using a medically accepted form of contraception
Who the study is looking for
- Age ≥18 years.
- Symptomatic HF defined as NYHA HF class II-IV within 1 month of enrolment
- LVEF ≤ 40% quantified by either echocardiography or gated SPECT ventriculography, or magnetic resonance (MR) or any other recognized assessment of LVEF
- Meaningful amount of myocardium at risk because of CAD (BCIS myocardial jeopardy score ≥ 6 on a recent (\> 6 months) coronary angiogram);
- Heart team believes that a meaningful revascularization can be achieved by both PCI or CABG, with complete revascularization defined as residual ischemia in \<10% of the left ventricle
- Heart team agrees that guideline directed medical therapy (GDMT) has been initiated for ≥1 month in prevalent and newly diagnosed cases. In patients hospitalized with newly diagnosed iLVSD (with or without acute coronary syndrome (ACS)) requiring revascularization before discharge, GDMT needs to be initiated, when possible, in-hospital before randomization, with the expectation that it will be titrated to maximally tolerated doses after revascularization
- Written informed consent obtained
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kardiologen Coordinator of this site? Confirm its status | Gothenburg | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.